MCA
NTLA icon

Maryland Capital Advisors’s Intellia Therapeutics NTLA Stock Holding History

Maryland Capital Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-153
Closed -$9K – 241
2022
Q3 		$9K Buy
+153
New +$9.49K 0.01% 169

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Maryland Capital Advisors's NTLA Position: Q4 2022 in Review

Maryland Capital Advisors sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 153 shares — an estimated $9K sold.

Maryland Capital Advisors first reported a position in NTLA in Q3 2022 and held it in 1 quarter. The position peaked at $9K in Q3 2022. 303 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • Maryland Capital Advisors reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Maryland Capital Advisors sold 153 Intellia Therapeutics shares in Q4 2022, an estimated $9K.
  • Maryland Capital Advisors first reported a position in Intellia Therapeutics in Q3 2022 and held it in 1 quarter.
  • Maryland Capital Advisors's Intellia Therapeutics position peaked at $9K in Q3 2022.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on Maryland Capital Advisors's 13F filing for Q4 2022, filed 18 Jan 2023.